The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy

Abstract

Overactive bladder is a syndrome characterised by urinary urgency, with or without urge incontinence, and usually with frequency and nocturia. It affects millions of people of all ages worldwide and causes significant morbidity, especially in terms of health-related quality of life. It poses a huge economic burden on health resources. Managing such patients involves a thorough history, physical examination and the use of pertinent investigations before the initiation of treatment. Therapy consists of lifestyle changes, bladder training, anticholinergics, second-line agents such as resiniferatoxin instillation or botulinum toxin injections into the bladder in refractory cases and, finally, in intractable cases, surgery. In the first part of this review of pharmacotherapy for the treatment of this condition, the focus is on the pathophysiological factors potentially involved in overactive bladder and covers the wide range of currently available first-line anticholinergic agents. Treatment algorithms are suggested on the basis of current literature.

Keywords::

• darifenacin
• detrusor overactivity
• health-related quality of life
• overactive bladder
• oxybutynin
• propiverine
• solifenacin
• tolterodine
• trospium chloride

View correction statement:

Erratum

Disclaimer

A Sahai and MS Khan are Investigators for Allergan Ltd.

Notes

Adapted from [146]. AG: Abrams–Griffith Score; HRQoL: Health-related quality of life; KHQ: King’s Health Questionnaire; OAB: Overactive bladder.